EX9 Stock Chart & Stats
€46.93
-€0.20(-0.40%)
At close: 4:00 PM EDT
€46.93
-€0.20(-0.40%)
Day’s Range― - ―
52-Week Range€29.61 - €52.26
Previous CloseN/A
Volume957.00
Average Volume (3M)37.00
Market Cap
€12.05B
Enterprise Value€13.83K
Total Cash (Recent Filing)€839.38M
Total Debt (Recent Filing)€165.93M
Price to Earnings (P/E)17.1
Beta0.39
Next Earnings
Nov 03, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding247,781,700
10 Day Avg. Volume5
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€44.88Price Target Upside-4.37% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)3.03
Revenue Forecast (FY)€2.20B
Bulls Say, Bears Say
Bulls Say
Leading Oncology Market PositionCABOMETYX is gaining prescriptions faster than its oral TKI market and expanding market share in important oncology settings. This leadership supports durable commercial momentum, strengthens physician adoption, and provides a substantial base for future franchise growth.
Strong Cash Generation And ProfitabilityHigh profitability and a substantial cash balance give Exelixis the resources to fund clinical development, pursue business development, and return capital without relying heavily on external financing. This financial capacity improves resilience as the pipeline advances.
Extended U.S. Product ExclusivityThe patent victory reinforces U.S. exclusivity for a key product and helps protect the revenue base from generic competition for several years. Greater commercial durability supports investment in the pipeline and provides more predictable funding for innovation.
Bears Say
Slower NET Commercial RampA slower NET uptake curve reduces near-term growth from an important expansion opportunity and shows that adoption may take longer than planned. Delayed patient initiation and treatment kinetics can make the revenue contribution less predictable over coming quarters.
Higher Gross-to-Net DeductionsHigher gross-to-net deductions reduce the net revenue captured from prescription demand and can pressure the sustainability of product margins. If these deductions persist, Exelixis may need stronger volume growth to achieve the same earnings and cash-flow outcomes.
Delayed Zanzalintinib ReviewThe regulatory extension pushes back a potential approval and commercial launch for a prospective next franchise. That delay lengthens the period before zanzalintinib can diversify revenue beyond cabozantinib and increases dependence on the existing portfolio.
Exelixis News
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was €29.61 and its highest was €52.26 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is €12.05B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Nov 03, 2026 which is in 49 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 05, 2026. The company reported €0.784 earnings per share for the quarter, beating the consensus estimate of €0.735 by €0.049.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.76.
How many shares outstanding does Exelixis have?
Exelixis has 247,781,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of €0.784 in its last earnings report, beating expectations of €0.735. Following the earnings report the stock price went down -4.623%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in DE:EX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€44.88 (-4.37% Downside)
€44.88 (-4.37% Downside)
Blogger Sentiment
Bullish
DE:EX9 Sentiment 69%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EX9 Company Deck
EX9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects strong commercial performance, healthy profitability and a well-advanced zanzalintinib development program with multiple pivotal trials and a pending NDA/PDUFA. These positive fundamentals are tempered by a modestly slower-than-expected NET ramp that prompted a $50 million downward adjustment to revenue guidance, higher gross-to-net expectations (30%–31%), and some clinical/regulatory uncertainties (STELLAR-303 subgroup result, 505(b)(2) dynamics). On balance, the company’s execution, cash position (~$1.4B), active share repurchases, and deep pipeline milestones outweigh the near-term headwinds, supporting a constructive outlook while acknowledging short-term risks.View all DE:EX9 earnings summariesEX9 Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EX9 Stock 12 Month Forecast
Average Price Target
€44.88
▼(-4.37% Downside)